Hulzebos Christian V, Wolters Henk, Plösch Torsten, Kramer Werner, Stengelin Siegfried, Stellaard Frans, Sauer Pieter J J, Verkade Henkjan J, Kuipers Folkert
Groningen University Institute for Drug Exploration, Center for Liver, Digestive, and Metabolic Diseases, Laboratory of Pediatrics, University Hospital Groningen, Groningen, The Netherlands.
J Pharmacol Exp Ther. 2003 Jan;304(1):356-63. doi: 10.1124/jpet.102.041640.
Cyclosporin A (CsA) has been shown to inhibit synthesis and hepatobiliary transport of bile salts. However, effects of CsA on the enterohepatic circulation of bile salts in vivo are largely unknown. We characterized the effects of CsA on the enterohepatic circulation of cholate, with respect to synthesis rate, pool size, cycling time, intestinal absorption, and the expression of relevant transporters in liver and intestine in rats. CsA (1 mg. 100 g(-1). day(-1) s.c.) or its solvent was administered daily to male rats for 10 days. Cholate synthesis rate and pool size were determined by a 2H4-cholate dilution technique. Bile and feces were collected for determination of cholate and total bile salts, respectively. Cycling time and intestinal absorption of cholate were calculated. The mRNA levels and corresponding transporter protein levels in liver and intestine were assessed by real-time polymerase chain reaction and Western analysis, respectively. CsA treatment decreased cholate synthesis rate by 71%, but did not affect pool size or cycling time. CsA reduced the amount of cholate lost per enterohepatic cycle by approximately 70%. Protein levels of the apical sodium-dependent bile salt transporter (Asbt) were 2-fold increased in distal ileum of CsA-treated rats, due to post-transcriptional events. In conclusion, chronic CsA treatment markedly reduces cholate synthesis rate in rats, but does not affect cholate pool size or cycling time. Our results strongly suggest that CsA enhances efficacy of intestinal cholate reabsorption through increased Asbt protein expression in the distal ileum, which contributes to maintenance of cholate pool size in CsA-treated rats.
环孢素A(CsA)已被证明可抑制胆盐的合成和肝胆转运。然而,CsA对体内胆盐肠肝循环的影响在很大程度上尚不清楚。我们研究了CsA对胆酸盐肠肝循环的影响,涉及合成速率、池大小、循环时间、肠道吸收以及大鼠肝脏和肠道中相关转运蛋白的表达。每天给雄性大鼠皮下注射CsA(1 mg·100 g⁻¹·天⁻¹)或其溶剂,持续10天。采用²H₄-胆酸盐稀释技术测定胆酸盐合成速率和池大小。分别收集胆汁和粪便以测定胆酸盐和总胆盐。计算胆酸盐的循环时间和肠道吸收。分别通过实时聚合酶链反应和蛋白质免疫印迹法评估肝脏和肠道中的mRNA水平及相应转运蛋白水平。CsA处理使胆酸盐合成速率降低了71%,但不影响池大小或循环时间。CsA使每个肠肝循环中损失的胆酸盐量减少了约70%。由于转录后事件,CsA处理的大鼠回肠末端顶端钠依赖性胆盐转运蛋白(Asbt)的蛋白质水平增加了2倍。总之,慢性CsA处理显著降低了大鼠胆酸盐的合成速率,但不影响胆酸盐池大小或循环时间。我们的结果强烈表明,CsA通过增加回肠末端Asbt蛋白表达来提高肠道胆酸盐重吸收效率,这有助于维持CsA处理大鼠的胆酸盐池大小。